NeuroVive Pharmaceutical AB Прогнозируемое соотношение цены к прибыли
Что обозначает Прогнозируемое соотношение цены к прибыли в NeuroVive Pharmaceutical AB?
Прогнозируемое соотношение цены к прибыли NeuroVive Pharmaceutical AB является N/A
Какое определение для Прогнозируемое соотношение цены к прибыли?
Отношение форвардной цены к прибыли - это отношение стоимости акций компании к расчетной прибыли компании на акцию в течение следующих двенадцати месяцев.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Что делает NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.